vimarsana.com

Latest Breaking News On - Her2 mutated nsclc - Page 1 : vimarsana.com

DESTINY-Lung04: First-Line Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Edward S. Kim, MD, MBA, discusses the DESTINY-Lung04 trial, a study evaluating trastuzumab deruxtecan as first-line treatment for patients with HER2 NSCLC.

The Role of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Experts on HER2 NSCLC discuss the patient populations in which they’d utilize trastuzumab deruxtecan and share their clinical experiences with the therapy.

Role of ADCs in HER2-Mutated NSCLC

The panel discusses the role of antibody-drug conjugates (ADCs) and the treatment of patients with HER2 non–small cell lung cancer.

Trastuzumab Deruxtecan Wins EU Approval for HER2-Mutated Advanced NSCLC

The European Commission has approved fam-trastuzumab deruxtecan-nxki for the treatment of patients with advanced non–small cell lung cancer whose tumors harbor an activating HER2 mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.